Daré Bioscience Prices $6M Registered Direct Offering with Warrants at $1.37
DARE sits 18% above its 52-week low of $0.765 on elevated volume (19× avg).
Summary
Daré Bioscience priced a $6 million registered direct offering at $1.37 per share, a premium to the current $0.90 price, with warrants that could add up to 8.76 million shares. The financing provides needed capital amid going concern and delisting risks.
Key Events · Financing and Capital Events · DARE
-
Registered Direct Offering Priced
Offering of 4,085,687 shares and 293,894 pre-funded warrants at $1.37 per share / $1.3699 per warrant, for gross proceeds of $6.0 million.
-
Concurrent Private Placement Warrants
Series A and B warrants to purchase up to 8,759,162 shares at $1.37 exercise price, subject to stockholder approval; if approved, warrants expire 5 and 2 years respectively.
-
Net Proceeds and Use
Net proceeds estimated at $5.4 million after fees; to be used for working capital, 503B compounding, consumer health, R&D, and general corporate purposes.
-
Lock-Up and Restrictions
Officers and directors subject to 60-day lock-up; company restricted from issuing securities for 60 days and from variable rate transactions for 180 days.
Analysis · DARE · Life Sciences
Daré Bioscience is raising $6 million in a registered direct offering priced at $1.37 per share, a premium to the current $0.90 market price. The deal includes pre-funded warrants and a concurrent private placement of Series A and B warrants that could add up to 8.76 million shares if exercised, subject to stockholder approval. This financing is critical for the company, which disclosed going concern doubt and a Nasdaq delisting hearing in late August. The capital extends the runway into Q4 2026, but the warrant overhang and potential dilution are significant for existing shareholders.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 989 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DARE was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.2M. The 52-week trading range was $0.77 to $3.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.